ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
12.73
-0.48 (-3.63%)
At close: Nov 6, 2026, 4:00 PM EST
12.74
+0.01 (0.08%)
After-hours: Nov 6, 2026, 7:30 PM EST
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ADMA Biologics stock has a consensus rating of "Buy" and an average price target of $17. The average 1-year stock price forecast is 33.54% higher than the current stock price, while the lowest is $12 (-5.73%) and the highest is $21 (+64.96%).
Price Target: $17 (+33.54%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $17 → $18 | Buy | Maintains | $17 → $18 | +41.40% | Nov 5, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +2.12% | Nov 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $18 → $19 | Buy | Reiterates | $18 → $19 | +49.25% | Nov 5, 2026 |
| Raymond James | Raymond James | Buy Initiates $21 | Buy | Initiates | $21 | +64.96% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
536.28M
from 510.17M
Increased by 5.12%
Revenue Next Year
629.41M
from 536.28M
Increased by 17.37%
EPS This Year
0.81
from 0.66
Increased by 23.34%
EPS Next Year
0.94
from 0.81
Increased by 16.46%
EPS and Forward PE are based on non-GAAP adjusted numbers.